Emily S. Ford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emily S. Ford has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
- Lawrence Corey
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
5 shared publications - Anton M. Sholukh
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA
4 shared publications - David M. Koelle
Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
4 shared publications - Christine Johnston
University of Washington
3 shared publications - Irini Sereti
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland
3 shared publications - Kerry J. Laing
Department of Medicine, University of Washington, Seattle, WA, USA
3 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (3) , e552-e555
First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients
Respiratory syncytial virus (RSV) infection causes substantial morbidity among hematopoietic cell transplant (HCT) patients and lacks approved therapies. Remdesivir demonstrates antiviral activity in vitro, but data in humans are lacking. We describe 5 HCT recipients with RSV lower respiratory tract infection who were treated with remdesivir with clinical improvement.
- 21 April 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (3) , e552-e555
Open AccessFirst Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients
Respiratory syncytial virus (RSV) infection causes substantial morbidity among hematopoietic cell transplant (HCT) patients and lacks approved therapies. Remdesivir demonstrates antiviral activity in vitro, but data in humans are lacking. We describe 5 HCT recipients with RSV lower respiratory tract infection who were treated with remdesivir with clinical improvement.
- Open Access
TCR2HLA: calibrated inference of HLA genotypes from TCR repertoires enables identification of immunologically relevant metaclonotypes
T cell receptors (TCRs) recognize peptides presented by polymorphic human leukocyte antigen (HLA) molecules, but HLA genotype data are often missing from TCR repertoire sequencing studies. To address this, we developed TCR2HLA, an open-source tool that infers HLA genotypes from TCRβ repertoires. Expanding on work linking public TRBV-CDR3 sequences to HLA genotypes, we incorporated “quasi-public” metaclonotypes – composed of rarer TCRβ sequences with shared amino acid features – enriched by HLA genotypes. Using four TCRβseq datasets from 3,150 individuals, we applied TRBV gene partitioning and locality-sensitive hashing to identify ∼96,000 TCRβ features strongly associated with specific HLA alleles from 71M input TCRs. Binary HLA classifiers built with these features achieved high balanced accuracy (>0.9) across common HLA-A (9/12), B (9/12), C (6/13), DRB1 (11/11) alleles and prevalent DPA1/DPB1 (6/10), DQA1/DQB1 (8/17) heterodimers. We also introduced a high-sensitivity calibration to support predictions in samples with as few as 5,000 unique clonotypes. Calibrated predictions with confidence filtering improved reliability. Beyond genotype imputation, TCR2HLA enables the discovery of novel HLA- and exposure-associated TCRs, as shown by the identification of SARS-CoV-2 related TCRs in a large COVID-19 dataset lacking HLA data. TCR2HLA provides a scalable framework for bridging the gap between TCRseq data and HLA genotype for biomarker discovery.
Open AccessTCR2HLA: calibrated inference of HLA genotypes from TCR repertoires enables identification of immunologically relevant metaclonotypes
T cell receptors (TCRs) recognize peptides presented by polymorphic human leukocyte antigen (HLA) molecules, but HLA genotype data are often missing from TCR repertoire sequencing studies. To address this, we developed TCR2HLA, an open-source tool that infers HLA genotypes from TCRβ repertoires. Expanding on work linking public TRBV-CDR3 sequences to HLA genotypes, we incorporated “quasi-public” metaclonotypes – composed of rarer TCRβ sequences with shared amino acid features – enriched by HLA genotypes. Using four TCRβseq datasets from 3,150 individuals, we applied TRBV gene partitioning and locality-sensitive hashing to identify ∼96,000 TCRβ features strongly associated with specific HLA alleles from 71M input TCRs. Binary HLA classifiers built with these features achieved high balanced accuracy (>0.9) across common HLA-A (9/12), B (9/12), C (6/13), DRB1 (11/11) alleles and prevalent DPA1/DPB1 (6/10), DQA1/DQB1 (8/17) heterodimers. We also introduced a high-sensitivity calibration to support predictions in samples with as few as 5,000 unique clonotypes. Calibrated predictions with confidence filtering improved reliability. Beyond genotype imputation, TCR2HLA enables the discovery of novel HLA- and exposure-associated TCRs, as shown by the identification of SARS-CoV-2 related TCRs in a large COVID-19 dataset lacking HLA data. TCR2HLA provides a scalable framework for bridging the gap between TCRseq data and HLA genotype for biomarker discovery.
- 13 May 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (6) , 1106-1114
Epidemiology of Healthcare Facility-Associated Nontuberculous Mycobacteria From 2012 Through 2020 in a 10-Hospital Network in the United States
Background: Data on the epidemiology of healthcare facility-associated (HCFA) nontuberculous mycobacteria (NTM) are sparse. We performed a multicenter longitudinal cohort study of HCFA NTM epidemiology. Methods: We retrospectively analyzed positive cultures for NTM performed from 2012 through 2020 within a network of 10 US academic hospitals and associated clinics. A unique NTM episode was defined as a patient's first positive culture for a particular NTM species and specimen source category (pulmonary vs extrapulmonary). Episodes linked to specimens obtained on day 3 or later of hospitalization were classified as hospital-onset (HO). Seven hospitals contributed at least 12 months of data prior to January 2014. Within this closed cohort, incidence rate ratios (IRRs) and trends in incidence from 2014 through 2020 were estimated, assuming the number of episodes followed the Poisson distribution. Results: A total of 12 855 unique NTM episodes occurred from 2012 through 2020 during 19 248 137 patient-days of surveillance. Of these episodes, 3045 (24%) were HO. HO incidence rates were highly variable among hospitals, with a median hospital rate of 1.06 episodes per 10 000 patient-days (range, 0.35–5.48). Within the 7-hospital closed cohort from 2014 through 2020, the incidence rate of HO episodes decreased from 2.29 to 1.42 episodes per 10 000 patient-days (IRR, 0.62; 95% confidence interval, .53–.73; P < .0001). Conclusions: Incidence rates of HO NTM episodes decreased from 2014 through 2020, but rates varied substantially among hospitals. These results provide comprehensive data on HO NTM isolation, including benchmark rates that can be used to improve hospital-based NTM surveillance.
- 13 May 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (6) , 1106-1114
Epidemiology of Healthcare Facility-Associated Nontuberculous Mycobacteria From 2012 Through 2020 in a 10-Hospital Network in the United States
Background: Data on the epidemiology of healthcare facility-associated (HCFA) nontuberculous mycobacteria (NTM) are sparse. We performed a multicenter longitudinal cohort study of HCFA NTM epidemiology. Methods: We retrospectively analyzed positive cultures for NTM performed from 2012 through 2020 within a network of 10 US academic hospitals and associated clinics. A unique NTM episode was defined as a patient's first positive culture for a particular NTM species and specimen source category (pulmonary vs extrapulmonary). Episodes linked to specimens obtained on day 3 or later of hospitalization were classified as hospital-onset (HO). Seven hospitals contributed at least 12 months of data prior to January 2014. Within this closed cohort, incidence rate ratios (IRRs) and trends in incidence from 2014 through 2020 were estimated, assuming the number of episodes followed the Poisson distribution. Results: A total of 12 855 unique NTM episodes occurred from 2012 through 2020 during 19 248 137 patient-days of surveillance. Of these episodes, 3045 (24%) were HO. HO incidence rates were highly variable among hospitals, with a median hospital rate of 1.06 episodes per 10 000 patient-days (range, 0.35–5.48). Within the 7-hospital closed cohort from 2014 through 2020, the incidence rate of HO episodes decreased from 2.29 to 1.42 episodes per 10 000 patient-days (IRR, 0.62; 95% confidence interval, .53–.73; P < .0001). Conclusions: Incidence rates of HO NTM episodes decreased from 2014 through 2020, but rates varied substantially among hospitals. These results provide comprehensive data on HO NTM isolation, including benchmark rates that can be used to improve hospital-based NTM surveillance.
- Open Access
- 18 June 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (14)
Expansion of the HSV-2–specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine
The skin at the site of HSV-2 reactivation is enriched for HSV-2–specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory T cells, we studied skin biopsies and HSV-2–reactive CD4 + T cells from PBMCs by T cell receptor (TCR) β chain ( TRB ) sequencing before and after vaccination with a replication-incompetent whole-virus HSV-2 vaccine candidate (HSV529). The representation of HSV-2–reactive CD4 + TRB sequences from PBMCs in the skin TRB repertoire increased after the first vaccine dose. We found sustained expansion after vaccination of unique, skin-based T cell clonotypes that were not detected in HSV-2–reactive CD4 + T cells isolated from PBMCs. In one participant, a switch in immunodominance occurred with the emergence of a TCR αβ pair after vaccination that was not detected in blood. This TCRαβ was shown to be HSV-2 reactive by expression of a synthetic TCR in a Jurkat-based NR4A1 reporter system. The skin in areas of HSV-2 reactivation possessed an oligoclonal TRB repertoire that was distinct from the circulation. Defining the influence of therapeutic vaccination on the HSV-2–specific TRB repertoire requires tissue-based evaluation.
- 18 June 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (14)
Open AccessExpansion of the HSV-2–specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine
The skin at the site of HSV-2 reactivation is enriched for HSV-2–specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory T cells, we studied skin biopsies and HSV-2–reactive CD4 + T cells from PBMCs by T cell receptor (TCR) β chain ( TRB ) sequencing before and after vaccination with a replication-incompetent whole-virus HSV-2 vaccine candidate (HSV529). The representation of HSV-2–reactive CD4 + TRB sequences from PBMCs in the skin TRB repertoire increased after the first vaccine dose. We found sustained expansion after vaccination of unique, skin-based T cell clonotypes that were not detected in HSV-2–reactive CD4 + T cells isolated from PBMCs. In one participant, a switch in immunodominance occurred with the emergence of a TCR αβ pair after vaccination that was not detected in blood. This TCRαβ was shown to be HSV-2 reactive by expression of a synthetic TCR in a Jurkat-based NR4A1 reporter system. The skin in areas of HSV-2 reactivation possessed an oligoclonal TRB repertoire that was distinct from the circulation. Defining the influence of therapeutic vaccination on the HSV-2–specific TRB repertoire requires tissue-based evaluation.
- 6 December 2023
- Published by Springer Nature in Nature Immunology
- Vol. 25 (1) , 166-177
Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hybrid immunity is more protective than vaccination or previous infection alone. To investigate the kinetics of spike-reactive T (TS) cells from SARS-CoV-2 infection through messenger RNA vaccination in persons with hybrid immunity, we identified the T cell receptor (TCR) sequences of thousands of index TS cells and tracked their frequency in bulk TCRβ repertoires sampled longitudinally from the peripheral blood of persons who had recovered from coronavirus disease 2019 (COVID-19). Vaccinations led to large expansions in memory TS cell clonotypes, most of which were CD8+ T cells, while also eliciting diverse TS cell clonotypes not observed before vaccination. TCR sequence similarity clustering identified public CD8+ and CD4+ TCR motifs associated with spike (S) specificity. Synthesis of longitudinal bulk ex vivo single-chain TCRβ repertoires and paired-chain TCRɑβ sequences from droplet sequencing of TS cells provides a roadmap for the rapid assessment of T cell responses to vaccines and emerging pathogens.
- 6 December 2023
- Published by Springer Nature in Nature Immunology
- Vol. 25 (1) , 166-177
Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hybrid immunity is more protective than vaccination or previous infection alone. To investigate the kinetics of spike-reactive T (TS) cells from SARS-CoV-2 infection through messenger RNA vaccination in persons with hybrid immunity, we identified the T cell receptor (TCR) sequences of thousands of index TS cells and tracked their frequency in bulk TCRβ repertoires sampled longitudinally from the peripheral blood of persons who had recovered from coronavirus disease 2019 (COVID-19). Vaccinations led to large expansions in memory TS cell clonotypes, most of which were CD8+ T cells, while also eliciting diverse TS cell clonotypes not observed before vaccination. TCR sequence similarity clustering identified public CD8+ and CD4+ TCR motifs associated with spike (S) specificity. Synthesis of longitudinal bulk ex vivo single-chain TCRβ repertoires and paired-chain TCRɑβ sequences from droplet sequencing of TS cells provides a roadmap for the rapid assessment of T cell responses to vaccines and emerging pathogens.
- Open Access
- 1 December 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (23)
Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity
Herpes zoster (HZ) is a substantial problem for people with decreased cell-mediated immunity, including older adults. The first vaccine approved for HZ prevention, the zoster vaccine live (ZVL), which provided limited and short-lived protection, has been supplanted by the superior recombinant zoster vaccine (RZV), which provides robust and durable protection. To understand the mechanisms underlying the differential immunologic characteristics of the 2 vaccines, we used T cell receptor β chain sequencing and peptide–MHC class II tetramer staining to analyze recombinant glycoprotein E–specific (gE-specific) CD4+ T cell clonotypes in RZV and ZVL recipients. Compared with ZVL, RZV expanded more gE-specific CD4+ clonotypes, with greater breadth and higher frequency of public clonotypes. RZV recruited a higher proportion of clonotypes from naive than from memory cells, while ZVL recruited equally from memory and naive compartments. Compared with memory-derived, naive-derived clonotypes were more likely to last 5 or more years after immunization. Moreover, the frequency of tetramer+ persistent clones correlated with the frequency of tetramer+ naive CD4+ prevaccination T cells. We conclude that the ability of RZV to recruit naive CD4+ T cells into the response may contribute to the durability of its effect. The abundance, breadth, and frequency of public clonotypes may further add to its protective effect.
- 1 December 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (23)
Open AccessRecruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity
Herpes zoster (HZ) is a substantial problem for people with decreased cell-mediated immunity, including older adults. The first vaccine approved for HZ prevention, the zoster vaccine live (ZVL), which provided limited and short-lived protection, has been supplanted by the superior recombinant zoster vaccine (RZV), which provides robust and durable protection. To understand the mechanisms underlying the differential immunologic characteristics of the 2 vaccines, we used T cell receptor β chain sequencing and peptide–MHC class II tetramer staining to analyze recombinant glycoprotein E–specific (gE-specific) CD4+ T cell clonotypes in RZV and ZVL recipients. Compared with ZVL, RZV expanded more gE-specific CD4+ clonotypes, with greater breadth and higher frequency of public clonotypes. RZV recruited a higher proportion of clonotypes from naive than from memory cells, while ZVL recruited equally from memory and naive compartments. Compared with memory-derived, naive-derived clonotypes were more likely to last 5 or more years after immunization. Moreover, the frequency of tetramer+ persistent clones correlated with the frequency of tetramer+ naive CD4+ prevaccination T cells. We conclude that the ability of RZV to recruit naive CD4+ T cells into the response may contribute to the durability of its effect. The abundance, breadth, and frequency of public clonotypes may further add to its protective effect.
- Open Access
- 4 February 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (5) , 289-292
Frequently Asked Questions about Mpox (Formerly Monkeypox Disease) for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Recipients from the American Society for Transplantation and Cellular Therapy
- 4 February 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (5) , 289-292
Open AccessFrequently Asked Questions about Mpox (Formerly Monkeypox Disease) for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Recipients from the American Society for Transplantation and Cellular Therapy
- Open Access
- 3 November 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (5) , 926-929
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir
A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.
- 3 November 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (5) , 926-929
Open AccessSuccessful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir
A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.
- Open Access
Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43
The human Betacoronavirus OC43 is a common cause of respiratory viral infections in adults and children. Lung infections with OC43 are associated with mortality, especially in hematopoietic stem cell transplant recipients. Neutralizing antibodies play a major role in protection against many respiratory viral infections, but to date a live viral neutralization assay for OC43 has not been described. We isolated a human monoclonal antibody (OC2) that binds to the spike protein of OC43 and neutralizes the live virus derived from the original isolate of OC43. We used this monoclonal antibody to develop and test the performance of two readily accessible in vitro assays for measuring antibody neutralization, one utilizing cytopathic effect and another utilizing an ELISA of infected cells. We used both methods to measure the neutralizing activity of the OC2 monoclonal antibody and of human plasma. These assays could prove useful for studying humoral responses to OC43 and cross-neutralization with other medically important betacoronaviruses.
Open AccessMethods to Measure Antibody Neutralization of Live Human Coronavirus OC43
The human Betacoronavirus OC43 is a common cause of respiratory viral infections in adults and children. Lung infections with OC43 are associated with mortality, especially in hematopoietic stem cell transplant recipients. Neutralizing antibodies play a major role in protection against many respiratory viral infections, but to date a live viral neutralization assay for OC43 has not been described. We isolated a human monoclonal antibody (OC2) that binds to the spike protein of OC43 and neutralizes the live virus derived from the original isolate of OC43. We used this monoclonal antibody to develop and test the performance of two readily accessible in vitro assays for measuring antibody neutralization, one utilizing cytopathic effect and another utilizing an ELISA of infected cells. We used both methods to measure the neutralizing activity of the OC2 monoclonal antibody and of human plasma. These assays could prove useful for studying humoral responses to OC43 and cross-neutralization with other medically important betacoronaviruses.
- 3 May 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (9)
B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin
Tissue-based T cells are important effectors in the prevention and control of mucosal viral infections; less is known about tissue-based B cells. We demonstrate that B cells and antibody-secreting cells (ASCs) are present in inflammatory infiltrates in skin biopsy specimens from study participants during symptomatic herpes simplex virus 2 (HSV-2) reactivation and early healing. Both CD20+ B cells, most of which are antigen inexperienced based on their coexpression of IgD, and ASCs — characterized by dense IgG RNA expression in combination with CD138, IRF4, and Blimp-1 RNA — were found to colocalize with T cells. ASCs clustered with CD4+ T cells, suggesting the potential for crosstalk. HSV-2–specific antibodies to virus surface antigens were also present in tissue and increased in concentration during HSV-2 reactivation and healing, unlike in serum, where concentrations remained static over time. B cells, ASCs, and HSV-specific antibody were rarely detected in biopsies of unaffected skin. Evaluation of samples from serial biopsies demonstrated that B cells and ASCs followed a more migratory than resident pattern of infiltration in HSV-affected genital skin, in contrast to T cells. Together, these observations suggest the presence of distinct phenotypes of B cells in HSV-affected tissue; dissecting their role in reactivation may reveal new therapeutic avenues to control these infections.
- 3 May 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (9)
B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin
Tissue-based T cells are important effectors in the prevention and control of mucosal viral infections; less is known about tissue-based B cells. We demonstrate that B cells and antibody-secreting cells (ASCs) are present in inflammatory infiltrates in skin biopsy specimens from study participants during symptomatic herpes simplex virus 2 (HSV-2) reactivation and early healing. Both CD20+ B cells, most of which are antigen inexperienced based on their coexpression of IgD, and ASCs — characterized by dense IgG RNA expression in combination with CD138, IRF4, and Blimp-1 RNA — were found to colocalize with T cells. ASCs clustered with CD4+ T cells, suggesting the potential for crosstalk. HSV-2–specific antibodies to virus surface antigens were also present in tissue and increased in concentration during HSV-2 reactivation and healing, unlike in serum, where concentrations remained static over time. B cells, ASCs, and HSV-specific antibody were rarely detected in biopsies of unaffected skin. Evaluation of samples from serial biopsies demonstrated that B cells and ASCs followed a more migratory than resident pattern of infiltration in HSV-affected genital skin, in contrast to T cells. Together, these observations suggest the presence of distinct phenotypes of B cells in HSV-affected tissue; dissecting their role in reactivation may reveal new therapeutic avenues to control these infections.